19.93

5.76% -1.2448

Intellia Therapeutics Inc (NTLA)

Overview News Price History Option Chain Discussions Forecast

Intellia Therapeutics Inc stock is currently priced at $19.93, with a 24-hour trading volume of 744.69K. It has seen a -5.76% decreased in the last 24 hours and a -25.64% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $21.31 pivot point. If it approaches the $20.19 support level, significant changes may occur.

Previous Close:

$21.17

Open:

$20.53

24h Volume:

744.69K

Market Cap:

$1.90B

Revenue:

$36.28M

Net Income/Loss:

$-481.19M

P/E Ratio:

-3.6493

EPS:

-5.46

Net Cash Flow:

$-408.07M

1W Performance:

-6.43%

1M Performance:

-25.64%

6M Performance:

-18.17%

1Y Performance:

-45.00%

1D Range:

$19.64

$20.66

52W Range:

$19.64

$47.48

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name

Intellia Therapeutics Inc

Sector

Healthcare (1201)

Industry

Biotechnology (688)

Phone

857-285-6200

Address

40 Erie Street, Suite 130, Cambridge, MA

Employee

195

Twitter

@intelliatweets

Next Earnings Date

2024-05-02

Latest SEC Filings

NTLA's Discussions on Twitter

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Apr-13-23	Initiated	Canaccord Genuity	Buy
Mar-21-23	Initiated	Bernstein	Outperform
Mar-14-23	Upgrade	BMO Capital Markets	Market Perform → Outperform
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight
Jan-24-23	Upgrade	Citigroup	Sell → Neutral
Jan-19-23	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Oct-11-22	Initiated	Morgan Stanley	Overweight
Sep-21-22	Initiated	JP Morgan	Overweight
Sep-01-22	Initiated	Citigroup	Sell
Jun-17-22	Initiated	BMO Capital Markets	Market Perform
Jun-16-22	Initiated	BofA Securities	Buy
Apr-28-22	Initiated	Credit Suisse	Outperform
Feb-18-22	Initiated	William Blair	Outperform
Feb-07-22	Upgrade	Oppenheimer	Perform → Outperform
Jan-31-22	Initiated	Cowen	Outperform
Jan-07-22	Initiated	Piper Sandler	Overweight
Oct-05-21	Initiated	Guggenheim	Buy
Sep-24-21	Initiated	Stifel	Buy
Jun-28-21	Reiterated	H.C. Wainwright	Buy
Jun-11-21	Initiated	H.C. Wainwright	Buy
May-07-21	Upgrade	ROTH Capital	Neutral → Buy
May-04-21	Initiated	RBC Capital Mkts	Outperform
Mar-04-21	Initiated	JMP Securities	Mkt Outperform
Dec-22-20	Downgrade	Robert W. Baird	Outperform → Neutral
Oct-27-20	Initiated	Truist	Buy
Oct-14-20	Initiated	Wells Fargo	Overweight
Sep-18-20	Initiated	Goldman	Buy
Feb-28-20	Upgrade	Oppenheimer	Perform → Outperform
Feb-14-20	Downgrade	Wedbush	Outperform → Neutral
Nov-01-19	Upgrade	Raymond James	Mkt Perform → Outperform
Jul-09-19	Initiated	Robert W. Baird	Outperform
Jun-10-19	Initiated	ROTH Capital	Neutral
May-03-19	Upgrade	Wedbush	Neutral → Outperform
Apr-12-19	Initiated	Evercore ISI	Outperform
Nov-02-18	Downgrade	Wedbush	Outperform → Neutral
Oct-29-18	Initiated	Credit Suisse	Neutral
Sep-21-18	Initiated	Raymond James	Mkt Perform
May-15-18	Upgrade	Chardan Capital Markets	Neutral → Buy
Mar-08-18	Initiated	JMP Securities	Mkt Outperform
Nov-01-17	Reiterated	Jefferies	Buy
Jun-22-17	Resumed	Jefferies	Buy
Mar-28-17	Initiated	Chardan Capital Markets	Buy
Aug-05-16	Upgrade	Jefferies	Hold → Buy

View All

Intellia Therapeutics Inc Stock (NTLA) Latest News

Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?

Zacks Investment Research

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline

Zacks Investment Research

Intellia Therapeutics Inc Stock (NTLA) Financials Data

Intellia Therapeutics Inc (NTLA) Revenue 2024

NTLA reported a revenue (TTM) of $36.27 million for the quarter ending December 31, 2023, a -30.40% decline year-over-year.

Intellia Therapeutics Inc (NTLA) Net Income 2024

NTLA net income (TTM) was -$481.19 million for the quarter ending December 31, 2023, a -1.48% decrease year-over-year.

Intellia Therapeutics Inc (NTLA) Cash Flow 2024

NTLA recorded a free cash flow (TTM) of -$408.07 million for the quarter ending December 31, 2023, a -4.19% decrease year-over-year.

Intellia Therapeutics Inc (NTLA) Earnings per Share 2024

NTLA earnings per share (TTM) was -$5.41 for the quarter ending December 31, 2023, a +12.46% growth year-over-year.

Intellia Therapeutics Inc Stock (NTLA) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Clark Eliana	EVP, Chief Technical Officer	Mar 04 '24	Sale	32.99	605	19,959	71,470
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Jan 08 '24	Sale	28.87	2,275	65,682	43,927
LEONARD JOHN M	President and CEO	Jan 03 '24	Sale	29.46	19,223	566,310	846,486
Lebwohl David	EVP, Chief Medical Officer	Jan 03 '24	Sale	29.46	5,843	172,135	54,372
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Jan 03 '24	Sale	29.46	5,532	162,973	46,202
Goddard Glenn	EVP, Chief Financial Officer	Jan 03 '24	Sale	29.46	5,365	158,053	40,585
Clark Eliana	EVP, Chief Technical Officer	Jan 03 '24	Sale	29.50	4,608	135,954	40,845
Hicks Derek	EVP, Chief Business Officer	Jan 03 '24	Sale	29.46	3,877	114,216	36,987
BASTA JAMES	EVP, General Counsel	Jan 03 '24	Sale	29.46	3,805	112,095	51,474
Bhanji Muna	Director	Oct 31 '23	Sale	23.90	265	6,334	11,996

Intellia Therapeutics, Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; and partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.